Travere Therapeutics (TVTX) Long-Term Deferred Tax (2015 - 2017)
Travere Therapeutics (TVTX) reported Long-Term Deferred Tax of $4.8 million for Q3 2017, down 44.22% quarter-over-quarter from $8.7 million in Q2 2015.
Travere Therapeutics (TVTX) Long-Term Deferred Tax (2015 - 2017) Analysis & Trends
Travere Therapeutics has reported Long-Term Deferred Tax for 2 years, with the latest figure at $4.8 million in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 4.85 Mn |
| Jun 30, 2015 | 8.69 Mn |
| Mar 31, 2015 | 8.69 Mn |